Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN 1999 "report card"

This article was originally published in The Tan Sheet

Executive Summary

FDA center completed "nearly 90%" of its "A" list goals in 1999, handling 73 of the 83 activities included in its yearly strategic plan. Among the achievements listed are the publication of a proposed rule on nutrient content/health claims based on authoritative statements for dietary supplements, holding five stakeholder meetings to address various supplement issues, publishing a guidance defining "significant scientific agreement" and developing a 10-year strategy for "achieving effective regulation of dietary supplements." Among the 10 unaccomplished activities, which "will be carried over to 2000," are "Ephedra" and "Infant Formula - Final Rules on GMPs and Quality Factors." CFSAN will announce its 2000 program priorities the week of Feb. 7

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel